BFRGW — Bullfrog AI Holdings, Inc. Warrants
NASDAQ · Healthcare · Health Information Services
$0.11
+$0.00 (+0.09%)
Bullfrog AI Holdings, Inc. Warrants (BFRGW) is a health information services company listed on NASDAQ. It is with about 2 employees. BullFrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. It offers bfLEAP, an AI/ML platform for the analysis of preclinical and/or clinical data. The company also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.
Latest reported BFRGW revenue for 2025-09-30 was $83.4K. Net income was -$1.6M. Revenue was up 150.8% from 2025-06-30 to 2025-09-30.
Use this BFRGW page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the BFRGW quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the BFRGW SEC filings page. Lician reads the product cache first so this HTML stays unique to Bullfrog AI Holdings, Inc. Warrants even when a live quote feed is slow.
About Bullfrog AI Holdings, Inc. Warrants
BullFrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. It offers bfLEAP, an AI/ML platform for the analysis of preclinical and/or clinical data. The company also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.
BFRGW Key Statistics
Market Cap
$0.00M
Volume
635
Previous Close
$0.11
Day Range
$0.11 – $0.11
EPS
-$0.85
Revenue
$0.00
Net Income
-$6.99M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-100.0%
Employees
2
BFRGW Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $65.00K | $10.00K | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$6.99M | -$5.36M | -$2.80M | -$585.84K |
| EPS (Diluted) | -$0.85 | -$0.89 | -$0.70 | $0.00 |
Total Assets
$5.55M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$5.44M
Operating Cash Flow
-$5.61M
Free Cash Flow
$0.00
Bullfrog AI Holdings, Inc. Warrants Company Information
- IPO / Founded
- 2023-02-14
- Sector
- Healthcare
- Industry
- Health Information Services